Digest Network Come funziona
Network
/
Società
Ru
Non verificato

Rubedo Life Sciences, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieSaluteTecnica

5 comunicati stampa

Guarda tutti i comunicati
26/03/2026
Eventi
Industria
Sanità
Software
Oncologia
Tecnica
Medicina - Varie
Scienza
Biotecnologia
Salute
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging
Fonte
Rubedo Life Sciences, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh
Fonte
Rubedo Life Sciences, Inc.
Emittente
Business Wire
1.00
0
17/09/2025
Tecnica
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Industria
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board
Fonte
Rubedo Life Sciences, Inc.
Emittente
Business Wire
1.00
0
22/05/2025
Industria
Biotecnologia
Farmaceutica
Salute
Tecnica
Medicina - Varie
Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Fonte
Rubedo Life Sciences, Inc.
Emittente
Business Wire
1.00
0
15/05/2025
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Fonte
Rubedo Life Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0